Elevation Oncology, Inc. (ELEV)
$1.02
-0.02 (-1.92%)
Rating:
Recommendation:
-
| Symbol | ELEV |
|---|---|
| Price | $1.02 |
| Beta | 0.000 |
| Volume Avg. | 0.08M |
| Market Cap | 23.767M |
| Shares () | - |
| 52 Week Range | 0.723-5.2 |
| 1y Target Est | - |
| DCF Unlevered | ELEV DCF -> | |
|---|---|---|
| DCF Levered | ELEV LDCF -> | |
| ROE | -99.07% | Strong Sell |
| ROA | -96.94% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 66.11% | Buy |
| P/E | 0.15 | Neutral |
| P/B | 0.35 | Neutral |
Latest ELEV news
About
Download (Excel)Dr. Shawn Leland Pharm.D., R.Ph.
Healthcare
Biotechnology
NASDAQ Global Select
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.